

Realheart Presents Positive Hematological Data at the American Society for Artificial Internal Organs 70th Annual Conference in Baltimore

Västerås, 10 April 2024 - Scandinavian Real Heart AB (publ) announces today that the company will participate in the annual conference organised by the American Society for Artificial Internal Organs (ASAIO). The conference brings together the world's leading scientists, clinicians, engineers and entrepreneurs in the development of artificial organs. Representatives from Realheart will attend the conference, which takes place in Baltimore, Maryland, USA between 29 May and 1 June.

During the conference, new study data will be presented that strengthens the company's previous results, which show that the company's artificial heart, Realheart® TAH, has a low damaging effect on red blood cells (hemolysis) compared to today's market-dominant heart pump system. The new results are based on in-depth analyses that include several blood components and further confirm that Realheart® TAH causes a significantly lower degree of blood damage.

ASAIO is an annual conference that brings together clinicians, scientists, engineers and companies involved in the research and development of artificial organs. The conference is also attended by representatives from the US Food and Drug Administration (FDA) and other public institutions.

Realheart will participate in the Bioengineering1 session, Thursday 30 June at 15.20, to present the scientific abstract "In Vitro Human Blood Damage Profile of the SynCardia TAH and the Realheart® TAH in a Full Body Circulation Test Rig".

Click on the link to read the abstract: www.asaio.org/conference/program/2024/BIO9.cgi.

About Realheart

Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trial models ahead of a first clinical study in patients expected to start in 2025. Realheart® TAH addresses a significant and urgent medical need - today 8,300 people around the world are waiting for a heart transplant and many patients unfortunately die during their time on the waiting list. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with very severe heart failure. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se

For more information, please contact:

Ina Laura Perkins, CEO

Phone: +46 (0) 70 406 49 21

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se